Is Midatech Pharma Plc – American Depositary Shares (NASDAQ:MTP) a Buy? The Stock Reported Less Sellers

June 2, 2018 - By Peter Erickson

Midatech Pharma Plc (NASDAQ:MTP) Logo

The stock of Midatech Pharma Plc – American Depositary Shares (NASDAQ:MTP) registered a decrease of 8.4% in short interest. MTP’s total short interest was 32,700 shares in June as published by FINRA. Its down 8.4% from 35,700 shares, reported previously. With 4,800 shares average volume, it will take short sellers 7 days to cover their MTP’s short positions. The short interest to Midatech Pharma Plc – American Depositary Shares’s float is 0.15%.

The stock decreased 0.77% or $0.005629 during the last trading session, reaching $0.720771. About 14,532 shares traded. Midatech Pharma Plc (NASDAQ:MTP) has declined 72.41% since June 2, 2017 and is downtrending. It has underperformed by 84.98% the S&P500.

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. The company has market cap of $23.57 million. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. It currently has negative earnings. The firm also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy.

Another recent and important Midatech Pharma Plc (NASDAQ:MTP) news was published by which published an article titled: “Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer” on May 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.